Big Pharma Approvals — July 18, 2026

Two separate FALLBACK label expansions for SELPERCATINIB (Eli Lilly) were approved, reinforcing the drug’s utility in RET-altered tumors. While revenue contribution is likely incremental, the dual approval signals regulatory confidence in expanded patient populations and could extend the product's commercial tail.

Merck received a label expansion for ENLICITIDE CHLORIDE, indicating the drug is being adapted to an additional indication via the FALLBACK route. Given Merck's dominance in oncology, this provides a modest upside to an already established brand.

SELPERCATINIB is a small molecule, making it subject to IRA Medicare price negotiation 9 years post-approval. With label expansions, cumulative patient populations increase, potentially raising IRA exposure exposure over time.

Both SELPERCATINIB and ENLICITIDE CHLORIDE label expansions were designated as 'FALLBACK' approvals, indicating they are secondary indications or switching studies rather than primary breakthrough indications—limiting peak sales potential and differentiation against competitors in those segments.

All three approvals in this period lack NCE or Orphan exclusivity, and with no disclosed exclusivity for these label expansions, each is vulnerable to generic or biosimilar competition as the original data exclusivity expires.

Eli Lilly’s two SELPERCATINIB label expansions open indications that could expand total addressable patient pop, supporting medium-term revenue resilience for the drug.

Merck Sharp & Dohme’s ENLICITIDE CHLORIDE expansion provides an additional lever to extract value from an existing product, supporting overall oncology portfolio growth.

Eli Lilly's dual SELPERCATINIB label expansions in the same period underscore an industry trend of extracting maximum value from NMEs via serial indication expansion. This strategy is common in targeted therapies where the same drug applies to multiple molecular subsets or tumor types.

All three approvals this period are label expansions with moderate bullish signals, functioning as 'pipeline filler' rather than transformative regulatory events. This pattern suggests a stable regulatory environment for established drugs seeking supplementary indications.

{"entity"=>"SELPERCATINIB (RETEVMO) - Eli Lilly", "reason"=>"Two label expansions in a single month signal aggressive lifecycle management; competitive environment from other RET inhibitors (e.g., pralsetinib, Blueprint Medicines) could limit commercial upside.", "trigger"=>"Retail and hospital formulary access decisions for new indications; competitor trial readouts"}

{"entity"=>"ENLICITIDE CHLORIDE - Merck Sharp & Dohme", "reason"=>"Label expansion from a FALLBACK approval suggests a potentially niche indication; peak sales contribution unknown.", "trigger"=>"Payer coverage finalization; upcoming earnings call disclosure of indication-specific revenue"}